Compare PBHC & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | TIL |
|---|---|---|
| Founded | 1859 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 74.7M |
| IPO Year | 2014 | 2021 |
| Metric | PBHC | TIL |
|---|---|---|
| Price | $13.62 | $8.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 3.2K | ★ 55.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | 46.25 | ★ 52.54 |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.06 | $5.67 |
| 52 Week High | $17.00 | $42.75 |
| Indicator | PBHC | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 52.04 |
| Support Level | $13.43 | $6.85 |
| Resistance Level | $13.75 | $9.81 |
| Average True Range (ATR) | 0.17 | 0.68 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 87.40 | 45.54 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.